Technical analysis of PepGen Inc. (PEPG): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Price Performance
| 1 month | -0.34% |
| 3 months | +62.01% |
| Year-to-date | -55.45% |
| 1 year | +55.08% |
| 3 years | -45.59% |
52-Week Range
| 52-week High | $7.80 |
| 52-week Low | $1.31 |
| Avg Volume (90d) | 876K |
Technical Indicators
| SMA 50 | $2.63 |
| SMA 200 | $3.56 |
| Beta | 2.34 |
| 30-day Volatility (annualised) | 87.3% |
| Price vs SMA 50 | +10.4% |
| Price vs SMA 200 | -18.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $4.66 | |
| 2025-11 | $6.44 | +38.2% |
| 2025-12 | $6.51 | +1.1% |
| 2026-01 | $5.13 | -21.2% |
| 2026-02 | $6.22 | +21.2% |
| 2026-03 | $1.77 | -71.5% |
| 2026-04 | $1.64 | -7.3% |
| 2026-05 | $1.50 | -8.5% |
| 2026-06 | $1.80 | +20.0% |
| 2026-07 | $1.76 | -2.2% |
| 2026-08 | $2.99 | +69.9% |
| 2026-09 | $2.90 | -3.0% |
Price
| Price | $2.90 |
| Market Cap | $201M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.70 |
| EV / EBITDA | -3.07 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.13 |
| Current Ratio | 13.36 |